Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04970966 · ClinicalTrials.gov registry record · NA
Efficacy of PuraSinus Versus Bioresorbable Nasal Dressings
A NA study, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04970966 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 30 participants.
The verdict
NCT04970966, a NA study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Postoperative care of patients undergoing endoscopic sinus surgery (ESS) is important both to minimize discomfort for the patients and to obtain the optimal long-term outcomes. Postoperative sinonasal cavity debridement has been advocated to prevent potential synechiae and sinus ostial stenosis, as well as to improve patient symptoms. Removal of old blood, nasal secretions, crusting, and unabsorbed packing are thought to reduce the inflammatory load, minimize potential for scarring, and allow for improved access of topical medications. However, the debridement procedure can cause bleeding, pain, and discomfort which may interfere with the effective execution of postoperative care. PuraSinus is a novel topical haemostatic agent based on nanotechnologies in the form of a transparent hydrogel suitable for endoscopic use and for which the use in sinonasal surgery could achieve these various goals. The potential of PuraSinus to enhance endoscopic mucosal wound healing may play a role in optimizing patient comfort during postoperative debridements after ESS. However, clinical evidence on its effectiveness in ESS is limited. The investigators aim to perform a randomized controlled trial to evaluate the efficacy of PuraSinus in improving patient comfort during postoperative debridements among patients who underwent ESS.
Interventions
- DEVICE PuraSinus
- DEVICE Bioresorbable Nasal Dressing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2024-05-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04970966
The ClinicalTrials.gov registry entry for NCT04970966 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PuraSinus is the first listed.
NCT04970966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04970966 about?
NCT04970966 is a clinical study titled "Efficacy of PuraSinus Versus Bioresorbable Nasal Dressings". Postoperative care of patients undergoing endoscopic sinus surgery (ESS) is important both to minimize discomfort for the patients and to obtain the optimal long-term outcomes. Postoperative sinonasal cavity debridement has been advocated to prevent potential synechiae and sinus ostial stenosis, as ...
What is the current status of trial NCT04970966?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2022-01-01. Estimated completion is 2024-05-05.
What interventions are being tested in trial NCT04970966?
The interventions under investigation include: PuraSinus (DEVICE), Bioresorbable Nasal Dressing (DEVICE).
Who is sponsoring clinical trial NCT04970966?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.